|
1
|
Erratum: Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 70:3132020. View Article : Google Scholar
|
|
2
|
den Brok WD, Speers CH, Gondara L, Baxter
E, Tyldesley SK and Lohrisch CA: Survival with metastatic breast
cancer based on initial presentation, de novo versus relapsed.
Breast Cancer Res Treat. 161:549–556. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ruddy KJ and Ganz PA: Treatment of
nonmetastatic breast cancer. JAMA. 321:1716–1717. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cardoso F, Senkus E, Costa A, Papadopoulos
E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh
J, et al: 4th ESO-ESMO international consensus guidelines for
advanced breast cancer (ABC 4)†. Ann Oncol. 29:1634–1657. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology-Breast Cancer
(Version 1, 2018). [DB/OL]. http://www.nccn.org
|
|
7
|
Liu P, Kumar IS, Brown S, Kannappan V,
Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL and Wang W:
Disulfiram targets cancer stem-like cells and reverses resistance
and cross-resistance in acquired paclitaxel-resistant
triple-negative breast cancer cells. Br J Cancer. 109:1876–1885.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Byrski T, Gronwald J, Huzarski T,
Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski
R, Siolek M, et al: Pathologic complete response rates in young
women with BRCA1-positive breast cancers after neoadjuvant
chemotherapy. J Clin Oncol. 28:375–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silver DP, Richardson AL, Eklund AC, Wang
ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et
al: Efficacy of neoadjuvant cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asano Y, Kashiwagi S, Goto W, Takada K,
Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M,
et al: Prediction of treatment responses to neoadjuvant
chemotherapy in triple-negative breast cancer by analysis of immune
checkpoint protein expression. J Transl Med. 16:872018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu K, Wang Y, Zhu Q, Li P, Chen J, Tang
Z, Shen Y, Cheng X, Lu LY and Liu Y: Aberrantly expressed HORMAD1
disrupts nuclear localization of MCM8-MCM9 complex and compromises
DNA mismatch repair in cancer cells. Cell Death Dis. 11:5192020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiao H, Rao HBDP, Yun Y, Sandhu S, Fong
JH, Sapre M, Nguyen M, Tham A, Van BW, Chng TYH, et al: Impeding
DNA break repair enables oocyte quality control. Mol Cell.
72:211–221.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen YT, Venditti CA, Theiler G, Stevenson
BJ, Iseli C, Gure AO, Jongeneel CV, Old LJ and Simpson AJ:
Identification of CT46/HORMAD1, an immunogenic cancer/testis
antigen encoding a putative meiosis-related protein. Cancer Immun.
5:92005.PubMed/NCBI
|
|
14
|
Adélaïde J, Finetti P, Bekhouche I,
Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N,
Desplans J, Parzy D, et al: Integrated profiling of basal and
luminal breast cancers. Cancer Res. 67:11565–11575. 2007.
View Article : Google Scholar
|
|
15
|
Shahzad MM, Shin YH, Matsuo K, Lu C,
Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, et
al: Biological significance of HORMA domain containing protein 1
(HORMAD1) in epithelial ovarian carcinoma. Cancer Lett.
330:123–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watkins J, Weekes D, Shah V, Gazinska P,
Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, et al:
Genomic complexity profiling reveals that HORMAD1 overexpression
contributes to homologous recombination deficiency in
triple-negative breast cancers. Cancer Discov. 5:488–505. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Tan Y, Cao X, Kim JA, Chen T, Hu
Y, Wexler M and Wang X: Epigenetic activation of HORMAD1 in
basal-like breast cancer: Role in Rucaparib sensitivity.
Oncotarget. 9:30115–30127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo SP, Jian L, Tao K, Chen C, Yu H and
Liu S: Novel breast-specific long non-coding RNA LINC00993 acts as
a tumor suppressor in triple-negative breast cancer. Front Oncol.
9:13252019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gebhart G, Lamberts L, Wimana Z, Garcia C,
Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, et
al: Molecular imaging as a tool to investigate heterogeneity of
advanced HER2-positive breast cancer and to predict patient outcome
under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Ann Oncol.
27:619–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Basu A: Regulation of autophagy by protein
kinase C-ε in breast cancer cells. Int J Mol Sci. 21:42472020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen B, Tang H, Chen X, Zhang G, Wang Y,
Xie X and Liao N: Transcriptomic analyses identify key
differentially expressed genes and clinical outcomes between
triple-negative and non-triple-negative breast cancer. Cancer Manag
Res. 11:179–190. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomioka N, Azuma M, Ikarashi M, Yamamoto
M, Sato M, Watanabe KI, Yamashiro K and Takahashi M: The
therapeutic candidate for immune checkpoint inhibitors elucidated
by the status of tumor-infiltrating lymphocytes (TILs) and
programmed death ligand 1 (PD-L1) expression in triple negative
breast cancer (TNBC). Breast Cancer. 25:34–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nichols BA, Oswald NW, McMillan EA,
McGlynn K, Yan J, Kim MS, Saha J, Mallipeddi PL, LaDuke SA,
Villalobos PA, et al: HORMAD1 is a negative prognostic indicator in
lung adenocarcinoma and specifies resistance to oxidative and
genotoxic stress. Cancer Res. 78:6196–6208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao J, Caballero OL, Yung WK, Weinstein
JN, Riggins GJ, Strausberg RL and Zhao Q: Tumor subtype-specific
cancer-testis antigens as potential biomarkers and
immunotherapeutic targets for cancers. Cancer Immunol Res.
2:371–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Levine B and Kroemer G: Biological
functions of autophagy genes: A disease perspective. Cell.
176:11–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang YB, Gong JL, Xing TY, Zheng SP and
Ding W: Autophagy protein p62/SQSTM1 is involved in HAMLET-induced
cell death by modulating apotosis in U87MG cells. Cell Death Dis.
4:e5502013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chick JM, Munger SC, Simecek P, Huttlin
EL, Choi K, Gatti DM, Raghupathy N, Svenson KL, Churchill GA and
Gygi SP: Defining the consequences of genetic variation on a
proteome-wide scale. Nature. 534:500–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aravind L and Koonin E: The HORMA domain:
A common structural denominator in mitotic checkpoints, chromosome
synapsis and DNA repair. Trends Biochem Sci. 23:284–286. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Daniel K, Lange J, Hached K, Fu J,
Anastassiadis K, Roig I, Cooke HJ, Stewart AF, Wassmann K, Jasin M,
et al: Meiotic homologue alignment and its quality surveillance are
controlled by mouse HORMAD1. Nat Cell Biol. 13:599–610. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nielsen AY and Gjerstorff MF: Ectopic
expression of testis germ cell proteins in cancer and its potential
role in genomic instability. Int J Mol Sci. 17:8902016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shin YH, Choi Y, Erdin SU, Yatsenko SA,
Kloc M, Yang F, Wang PJ, Meistrich ML and Rajkovic A: Hormad1
mutation disrupts synaptonemal complex formation, recombination,
and chromosome segregation in mammalian meiosis. PLoS Genet.
6:e10011902010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nanji T, Liu X, Chew LH, Li FK, Biswas M,
Yu ZQ, Lu S, Dong MQ, Du LL, Klionsky DJ and Yip CK: Conserved and
unique features of the fission yeast core Atg1 complex. Autophagy.
13:2018–2027. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galluzzi L, Baehrecke EH, Ballabio A, Boya
P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P,
Colombo MI, et al: Molecular definitions of autophagy and related
processes. EMBO J. 36:1811–1836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Acquaviva L, Boekhout M, Karasu ME, Brick
K, Pratto F, Li T, van Overbeek M, Kauppi L, Camerini-Otero RD,
Jasin M and Keeney S: Ensuring meiotic DNA break formation in the
mouse pseudoautosomal region. Nature. 582:426–431. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng A, Liang X, Zhu S, Liu C, Luo X,
Zhang Q and Song L: Baicalin, a potent inhibitor of NF-κB signaling
pathway, enhances chemosensitivity of breast cancer cells to
docetaxel and inhibits tumor growth and metastasis both in vitro
and in vivo. Front Pharmacol. 11:8792020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singh SK, Apata T, Gordetsky JB and Singh
R: Docetaxel combined with thymoquinone induces apoptosis in
prostate cancer cells via inhibition of the PI3K/AKT signaling
pathway. Cancers (Basel). 11:11392019. View Article : Google Scholar
|
|
38
|
Zhang X, Shao J, Li X, Cui L and Tan Z:
Docetaxel promotes cell apoptosis and decreases SOX2 expression in
CD133-expressing hepatocellular carcinoma stem cells by suppressing
the PI3K/AKT signaling pathway. Oncol Rep. 41:1067–1074.
2019.PubMed/NCBI
|
|
39
|
Dávila-González D, Choi DS, Rosato RR,
Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski
AJ, Wong H, et al: Pharmacological inhibition of NOS activates
ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in
triple-negative breast cancer. Clin Cancer Res. 24:1152–1162. 2018.
View Article : Google Scholar
|
|
40
|
Byrski T, Gronwald J, Huzarski T,
Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski
R, Siolek M, et al: Response to neo-adjuvant chemotherapy in women
with BRCA1-positive breast cancers. Breast Cancer Res Treat.
108:289–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL,
Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR IV, et al: Blocking
c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of
PARP inhibitors. Nat Med. 22:194–201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schlacher K: A new road to cancer-drug
resistance. Nature. 563:478–480. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shahzad MM, Lu C, Lee JW, Stone RL, Mitra
R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, et al: Dual
targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther.
8:1027–1034. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gao Y, Kardos J, Yang Y, Tamir TY,
Mutter-Rottmayer E, Weissman B, Major MB, Kim WY and Vaziri C: The
cancer/testes (CT) antigen HORMAD1 promotes homologous
recombinational DNA repair and radioresistance in lung
adenocarcinoma cells. Sci Rep. 8:153042018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dubois C, Martin F, Hassel C, Magnier F,
Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F and
Bamdad M: Low-dose and long-term Olaparib treatment sensitizes
MDA-MB-231 and SUM1315 triple-negative breast cancers spheroids to
fractioned radiotherapy. J Clin Med. 9:642019. View Article : Google Scholar : PubMed/NCBI
|
